Sharemaestro company-news research for Motor Oil (Hellas) Corinth Refineries S.A. (MOH), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

ATH Greece Measured evidence

Company news sentiment

MOH news sentiment

Motor Oil (Hellas) Corinth Refineries S.A.

Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.

Weighted tone59Neutral is 50
Constructive news tone 46/100 evidence confidence 100% direct company focus 2 current stories across 1 publishers
SectorEnergywider market group
Latest weekly closeEUR 53.00week of 7 Aug 2026
Dominant catalystEarnings75/100 classification confidence
News data statusHealthy0 duplicate stories removed

Current company news

News confirmed by price

Constructive news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 1 publishers.

Latest source headline CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong finance.yahoo.com · 07 Aug 2026 18:22

What supports the read

Direct evidence

2 current stories are mapped specifically to MOH.

Narrative agreement

Cross-story agreement is 83/100, indicating a comparatively coherent tape.

Price response

Constructive news tone is being confirmed by positive weekly price action.

What tempers the read

Source breadth

Only 1 publisher currently contribute to the measured read.

59/100
Weighted toneConstructive news tone
46/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
83/100
Evidence agreement17/100 dispersion

News history

Tone and story flow over 21 days

Daily weighted evidence
07 Aug: 2 stories 07 Aug: tone 70, 2 stories 95505
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50

Evidence confidence

What supports the score

Measured separately from tone

Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.

Sample depth24
1.89 effective stories
Source breadth20
1 independent publishers
Direct relevance100
company-specific evidence share
Freshness40
recency-weighted evidence
Agreement83
cross-story consistency
Source independence0
lower publisher concentration

Price context

Sentiment against the 26-week price path

News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

13 Feb 2026: close 35.52, indexed 100.020 Feb 2026: close 35.0, indexed 98.527 Feb 2026: close 36.68, indexed 103.306 Mar 2026: close 36.7, indexed 103.313 Mar 2026: close 37.6, indexed 105.920 Mar 2026: close 39.12, indexed 110.127 Mar 2026: close 37.22, indexed 104.803 Apr 2026: close 38.9, indexed 109.510 Apr 2026: close 38.46, indexed 108.317 Apr 2026: close 36.52, indexed 102.824 Apr 2026: close 33.58, indexed 94.501 May 2026: close 36.62, indexed 103.108 May 2026: close 34.89, indexed 98.215 May 2026: close 34.27, indexed 96.522 May 2026: close 33.37, indexed 93.929 May 2026: close 35.64, indexed 100.305 Jun 2026: close 38.49, indexed 108.412 Jun 2026: close 38.43, indexed 108.219 Jun 2026: close 36.62, indexed 103.126 Jun 2026: close 38.14, indexed 107.403 Jul 2026: close 41.4, indexed 116.610 Jul 2026: close 47.0, indexed 132.317 Jul 2026: close 47.0, indexed 132.324 Jul 2026: close 50.5, indexed 142.231 Jul 2026: close 50.8, indexed 143.007 Aug 2026: close 53.0, indexed 149.2 20 Jun 2026: sentiment 5221 Jun 2026: sentiment 5322 Jun 2026: sentiment 5422 Jun 2026: sentiment 5622 Jun 2026: sentiment 5622 Jun 2026: sentiment 5623 Jun 2026: sentiment 5724 Jun 2026: sentiment 5126 Jun 2026: sentiment 4927 Jun 2026: sentiment 4930 Jun 2026: sentiment 5001 Jul 2026: sentiment 5002 Jul 2026: sentiment 5004 Jul 2026: sentiment 5004 Jul 2026: sentiment 5006 Jul 2026: sentiment 5008 Jul 2026: sentiment 5010 Jul 2026: sentiment 5011 Jul 2026: sentiment 5018 Jul 2026: sentiment 5019 Jul 2026: sentiment 5021 Jul 2026: sentiment 5523 Jul 2026: sentiment 5223 Jul 2026: sentiment 5223 Jul 2026: sentiment 5223 Jul 2026: sentiment 5227 Jul 2026: sentiment 5627 Jul 2026: sentiment 5628 Jul 2026: sentiment 6129 Jul 2026: sentiment 6129 Jul 2026: sentiment 6630 Jul 2026: sentiment 6631 Jul 2026: sentiment 6602 Aug 2026: sentiment 6102 Aug 2026: sentiment 5812 Aug 2026: sentiment 58
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
26-week price+49.2%latest close 53.0
Sentiment change+6available snapshot window
One-week response+4.3%Price confirming higher
Fair-value position+108.8%Materially above fair value
Sentiment confirms active trendPositive but stretched

News subjects

What is shaping the score

Earnings
Earnings702 stories · 100%

Source mix

Where the evidence comes from

0/100 independence
finance.yahoo.com702 stories · 100%

Recurring subjects

Subjects appearing most often

Current evidence
Earnings2Pharma1Net Income1Fourth Quarter1Fda Approval1Earnings Per Share1Earnings Growth1Defense1Clinical Trials1Biotech1

Earlier readings

How the score has changed

50 is the neutral baseline
ConstructiveBalanced or withheldCautious

Source headlines

The news behind the score

Showing 1-2 of 2

Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.

#148Tone
finance.yahoo.comDirect company coverage

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo and lower revenues. Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million. Cytokinetics' shares have surged 28.1% year to date compared with the ind

BiotechClinical TrialsEarningsFda ApprovalFourth QuarterPharma
Published
07 Aug 2026 18:22
Catalyst
Earnings
Evidence role
Direct company coverage
Duplicates
1 consolidated
#284Tone
finance.yahoo.comDirect company coverage

Bittium Oyj (HLSE:BITTI) Earnings Reset The Valuation Debate

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. How Bittium Oyj's Latest Earnings Shape the Investment Picture Bittium Oyj (HLSE:BITTI) reported half year 2026 sales of €57.9 million and net income of €7.5 million, compared with €42.3 million and €1.5 million a year earlier, which sharpened investor focus on the stock. Those figures, together with basic earnings per share from continuing operations of €0.211 compared with €0.043 a year ago, provide fresh data to reassess

Balance SheetDefenseEarningsEarnings GrowthEarnings Per ShareNet Income
Published
07 Aug 2026 18:10
Catalyst
Earnings
Evidence role
Direct company coverage
Duplicates
1 consolidated

How the page works

How to read the score

Tone is directional

It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

Classification, not prediction

The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.

Evidence context